Indeed, the anti-Aβ monoclonal antibodies, lecanemab and donanemab, reduce the deposition of tau pathology in patients with Alzheimer’s disease (AD), possibly via the removal of upstream amyloid plaques [9–11]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.